A Phase 2 interventional study of OPC-41061(Tolvaptan) in Heart Failure, Congestive and Edema, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-12-25.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.
Among the 19 studies testing tolvaptan in Heart Failure, this one is the 7th largest by enrollment, is one of 2 that started in 2004, is one of 4 in phase 2, and was the 6th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →
Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 60 across the 19 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
17 studies in Heart Failure by Otsuka Holdings Co., Ltd.: none open now, 1 under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2004, is one of 6 in phase 2, and was the 6th registered.
Otsuka Holdings Co., Ltd.’s Heart Failure studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing tolvaptan in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 17 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This drug is being developed to treat cardiac edema. The primary purpose of this study is to investigate the dose response for body weight in seven-day repeated oral administration of OPC-41061 at 15, 30, and 45 mg or placebo in patients with extracellular volume expansion secondary to CHF despite taking furosemide at 40 mg/d or more. This study is being conducted in Japan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who have undergone or are scheduled to undergo any of the following procedures
Patients with any of the following diseases, complications, or symptoms
Patients with a history of the following conditions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Body Weight
The body weight change from baseline following final trial drug administration
Time frame: Baseline, at the time of final trial drug administration
| Milestone | Placebo | 15 mg of OPC-41061 | 30 mg of OPC-41061 | 45 mg of OPC-41061 |
|---|---|---|---|---|
| Started | 30 | 29 | 34 | 29 |
| Completed | 26 | 28 | 29 | 21 |
| Not completed | 4 | 1 | 5 | 8 |
| Withdrew: Adverse event | 4 | 0 | 3 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 2 | 2 |
The body weight change from baseline following final trial drug administration
| Kg | Placebo | 15 mg of OPC-41061 | 30 mg of OPC-41061 | 45 mg of OPC-41061 |
|---|---|---|---|---|
| Body Weight | -0.53 ± 0.96 | -1.62 ± 1.55 | -1.35 ± 1.54 | -1.85 ± 1.10 |
Collected over 7 days. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/29 (13.8%) | 14/29 (48.3%) |
| 15 mg of OPC-41061 | — | 0/28 (0%) | 21/28 (75%) |
| 30 mg of OPC-41061 | — | 1/33 (3%) | 25/33 (75.8%) |
| 45 mg of OPC-41061 | — | 2/28 (7.1%) | 21/28 (75%) |
| Event | Placebo | 15 mg of OPC-41061 | 30 mg of OPC-41061 | 45 mg of OPC-41061 |
|---|---|---|---|---|
| Transient Ischaemic AttackNervous system disorders | 0/29 | 0/28 | 0/33 | 1/28 |
| Dyspnoea ExertionalRespiratory, thoracic and mediastinal disorders | 0/29 | 0/28 | 0/33 | 1/28 |
| Cardiac Failure CongestiveCardiac disorders | 1/29 | 0/28 | 0/33 | 0/28 |
| Cardio-Respiratory ArrestCardiac disorders | 1/29 | 0/28 | 0/33 | 0/28 |
| Umbilical HerniaGastrointestinal disorders | 1/29 | 0/28 | 0/33 | 0/28 |
| Sudden DeathGeneral disorders | 1/29 | 0/28 | 0/33 | 0/28 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/29 | 0/28 | 1/33 | 0/28 |
| Event | Placebo | 15 mg of OPC-41061 | 30 mg of OPC-41061 | 45 mg of OPC-41061 |
|---|---|---|---|---|
| ThirstGeneral disorders | 3/29 | 6/28 | 9/33 | 15/28 |
| Blood Uric Acid IncreasedInvestigations | 0/29 | 6/28 | 4/33 | 2/28 |
| DehydrationMetabolism and nutrition disorders | 2/29 | 0/28 | 3/33 | 6/28 |
| ConstipationGastrointestinal disorders | 3/29 | 1/28 | 6/33 | 1/28 |
| Blood Urea IncreasedInvestigations | 1/29 | 3/28 | 2/33 | 2/28 |
| DizzinessNervous system disorders | 0/29 | 3/28 | 1/33 | 2/28 |
| HeadacheNervous system disorders | 0/29 | 3/28 | 0/33 | 0/28 |
| Protein Urine PresentInvestigations | 3/29 | 0/28 | 1/33 | 0/28 |
| DiarrhoeaGastrointestinal disorders | 0/29 | 1/28 | 3/33 | 1/28 |
| Cardiac Failure CongestiveCardiac disorders | 0/29 | 0/28 | 1/33 | 2/28 |
1 Subject of each arm were excluded form the analysis set because emergency codes were lost.
| Age, Categorical(Participants) | Placebo | 15 mg of OPC-41061 | 30 mg of OPC-41061 | 45 mg of OPC-41061 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 10 | 11 | 14 | 46 |
| >=65 years | 18 | 18 | 22 | 14 | 72 |
| Age Continuous(years) | Placebo | 15 mg of OPC-41061 | 30 mg of OPC-41061 | 45 mg of OPC-41061 | Total |
|---|---|---|---|---|---|
| Mean | 67.9 ± 9.4 | 66.9 ± 9.6 | 66.4 ± 12.5 | 62.6 ± 12.5 | 66.0 ± 11.2 |
| Sex: Female, Male(Participants) | Placebo | 15 mg of OPC-41061 | 30 mg of OPC-41061 | 45 mg of OPC-41061 | Total |
|---|---|---|---|---|---|
| Female | 11 | 13 | 8 | 4 | 36 |
| Male | 18 | 15 | 25 | 24 | 82 |
| Region of Enrollment(participants) | Placebo | 15 mg of OPC-41061 | 30 mg of OPC-41061 | 45 mg of OPC-41061 | Total |
|---|---|---|---|---|---|
| Japan | 29 | 28 | 33 | 28 | 118 |
The record gives a start of Aug 2004, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 7 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →